Novartis to pay $310 million for assets from inflammation specialist IFM Garima2 April 2019 9:00 AM ISTIFM, whose research head Martin Seidel spent more than a decade at Novartis before assuming R&D duties at IFM in 2017, focuses on immune system...
Tiny stem cell companies close in on major heart disease goals Ruby Khatun Khatun20 Dec 2017 9:30 AM ISTNEW YORK: The early hope that stem cell therapy would make the paralyzed walk, the blind see and cure diabetes has given way to a long list of...
More than 2,000 drugs now in cancer immunotherapy race Ruby Khatun Khatun9 Dec 2017 10:00 AM ISTLONDON: The race to develop new immunotherapy treatments against cancer has sparked an unprecedented explosion in the oncology drug pipeline, with...
Cipla gets WHO approval to sell TB preventing drug in HIV patients Ruby Khatun Khatun1 Dec 2017 2:40 PM ISTNew Delhi: Drug major Cipla said it has received approval from the World Health Organisation (WHO) for Q-TIB, a combination drug indicated to help...
Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial Ruby Khatun Khatun1 Dec 2017 9:30 AM ISTFRANKFURT: Germany's Merck KGaA has suffered a setback in the development of key cancer immunotherapy Bavencio, it has failed in a trial to prolong...
This 5 billion dollars startup made its first Cancer vaccine - for just one person Ruby Khatun Khatun18 Nov 2017 10:15 AM ISTBy Caroline ChenFor Moderna Therapeutics, the road to a cancer breakthrough begins on the back of a FedEx truck.Six weeks ago, a 1-millimeter cube of...
Britain backs GSK gene therapy for BUBBLE BOY syndrome Ruby Khatun Khatun23 Oct 2017 9:32 AM ISTGlaxoSmithKline's (GSK) gene therapy for the so-called "bubble boy" disease was approved by Britain's healthcare cost watchdog NICE, despite a price...
